Quanren Wang

Quanren Wang

Jiangsu Hengrui Medicine Co,.Ltd - / China
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4970731
person_outline Quanren Wang's MOST POPULAR ARTICLES
1-) Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial Clinical Cancer Research 27 (4), 1003-1011, 2021
2-) Anti-PD-1 antibody SHR-1210 combined with Apatinib for advanced hepatocellular carcinoma, gastric, or Esophagogastric junction Cancer: an open-label, dose escalation and … Clinical Cancer Research 25 (2), 515-523, 2019
3-) HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib Annals of Oncology 30 (3), 447-455, 2018
4-) Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial Journal for immunotherapy of cancer 8 (1), 2020
5-) Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706) Journal of Thoracic Oncology 16 (9), 1533-1546, 2021